Pay in 4 interest-free payments of $7.04 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
10.1371/journal.pone.0012226 85
The landscape of metabolic pharmacotherapy is moving at a staggering pace
Curone M, Tullo V
While we anticipate retatrutide being a strong option for many people seeking weight loss, it may be particularly useful for anyone who falls into one or more of these categories: Didnt respond to earlier GLP-1 drugs like Wegovy, Ozempic, Rybelsus, Liraglutide, Zepbound, Mounjaro, etc Plateaued with other GLP-1s but still havent met your target weight Have a large body percentage of weight to lose (20% or more) Retatrutide is currently undergoing clinical trials necessary for it to obtain FDA approval (which is anticipated by summer) , so it's not yet available to be prescribed
What we dont know: As of now, however, there are zero randomized clinical trials studying BPC 157 in humans
Retatrutide is a triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, whereas semaglutide activates only the GLP-1 receptor and tirzepatide activates GLP-1 and GIP receptors
US$ 28.26
US$ 21.94
US$ 22.15
